POLYMORPHIC VARIANTS IN THE CYP3A4 GENE, CYSTIC FIBROSIS, AND THE RISK OF ADVERSE REACTIONS TO ANTIBACTERIAL THERAPY IN CHILDREN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic pulmonary infection is a consequence of impaired mucociliary clearance in cystic fibrosis (CF). Patients with CF receive long-term cycles of high-dose antibacterial therapy (ABT). A study of the causes of antibiotic resistance and adverse reactions (ARs) is promising in these patients. The impact of polymorphic variants in the CYP3A4 gene on the risk of ARs during ABT and on the predisposition to gram-negative infection was investigated in children with CF.

Full Text

Restricted Access

About the authors

O. Novoselova

Research Center of Medical Genetics; N.F. Filatov City Children's Hospital Thirteenth

E. Kondratyeva

Research Center of Medical Genetics

N. Petrova

Research Center of Medical Genetics

R. Bikanov

Research Center of Medical Genetics

R. Zinchenko

Research Center of Medical Genetics; N.I. Pirogov Russian National Research Medical Universit

Email: lgnovoselova@gmail.com

References

  1. Hersh A., Shapiro D., Pavia A. et al. Antibiotic prescribing in ambulatory pediatrics in the United States // Pediatrics. - 2011; 128: 1053-61.
  2. Versporten A., Sharland M., Bielicki J. et al. ARPEC Project Group Members. The Antibiotic Resistance and Prescribing in European Children Project: a neonatal and pediatric antimicrobial Web-based point prevalence survey in 73 hospitals worldwide // Pediatr. Infect. Dis. J. - 2013; 32: e242-53.
  3. Anderson B., Holford N. Tips and traps analyzing pediatric PK data // Paediatr. Anaesth. - 2011; 21: 222-37.
  4. Капранов Н.И., Каширская Н.Ю., Ашерова И.К. и др. Исторические и современные аспекты муковисцидоза в России // Педиатрическая фармакология. - 2013; 10 (6): 53-60.
  5. Gibson R., Burns J., Ramsey B. Pathophysiology and management of pulmonary infections in cystic fibrosis // Am. J. Respir. Crit. Care Med. - 2003; 168 (8): 918-51.
  6. Mishra A., Greaves R., Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era // Clin. Biochem. Rev. - 2005; 26 (4): 135-53.
  7. Koch C., Cuppens H., Rainisio M. et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations // Pediatr. Pulmonol. - 2001; 31 (1): 1-12.
  8. Муковисцидоз. Под ред. Н.И. Капранова, Н.Ю. Каширской / М.: МЕДПРАКТИКА-М, 2014; 672 с
  9. Tramper-Stranders G., van der Ent C., Molin S. et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates // Clin. Microbiol. Infect. - 2012; 18 (6): 567-74.
  10. Ашерова И.К., Капранов Н.И. Муковисцидоз - медико-социальная проблема // М.: ООО «Типография Ярославский печатный двор», 2013; 236 с.
  11. Национальный консенсус «Муковисцидоз: определение, диагностические критерии, терапия». Под ред. Е.И. Кондратьевой, Н.Ю. Каширской, Н.И. Капранова / М: ООО «Компания БОРГЕС», 2016; 205 с.
  12. Шагинян И.А., Капранов Н.И., Чернуха М.Ю. и др. Микробный пейзаж нижних дыхательных путей у различных возрастных групп детей, больных муковисцидозом // Журн. микробиол., эпидемиол. и инфекц. болезней. -2009; 5: 15-20.
  13. Guss A., Roeselers G., Newton I. et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis // ISMEJ. - 2011; 5 (1): 20-9.
  14. Красовский С.А., Черняк А.В., Кондратьева Е.И. и др. Муковисцидоз в России: создание национального регистра // Педиатрия. Журн. им. Г.Н. Сперанского. - 2014; 93 (4): 44-55.
  15. Sgro C., Clinard F., Ouazir K. et al. Incidence of drug-induced hepatic injuries: A French populationbased study // Hepatology. - 2002; 36: 451-5. [PubMed: 12143055]
  16. Ostapowicz G., Fontana R., Schiodt F. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States // Ann. Intern. Med. - 2002; 137: 947-54. [PubMed: 12484709]
  17. Wedi B. Definitions and mechanisms of drug hypersensitivity // Expert Rev. Clin. Pharmacol. - 2010; 3 (4): 539-51. [PubMed: 22111682]
  18. Johansson S., Hourihane J., Bousquet J. et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force // Allergy. - 2001; 56 (9): 813-24. [PubMed: 11551246]
  19. Posadas S., Pichler W. Delayed drug hypersensitivity reactions - new concepts // Clin. Exp. Allergy. - 2007; 37 (7): 989-99. [PubMed: 17581192]
  20. Sim S., Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects // Human Genomics. - 2010; 4 (4): 278-81. doi: 10.1186/1479-7364-4-4-278.
  21. http://www.cypalleles.ki.se/
  22. Sim S., Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects // Human Genomics. - 2010; 4 (4): 278-81. doi: 10.1186/1479-7364-4-4-278.
  23. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research // Toxicol. Appl. Pharmacol. - 2005; 207 (2 Suppl.): 52-6.
  24. Guengerich F. Cytochrome p450 and chemical toxicology // Chem. Res. Toxicol. - 2008; 21 (1): 70-83.
  25. The Pharmacogenomics Knowledge Base. CPIC Gene-Drug Pairs. http:// www.pharmgkb.org/page/cpicGeneDrugPairs. Accessed April 2, 2014.
  26. Kisor D., Kane M., Talbot J. et al. Introduction to Personalized Medicine. In: Pharmacogenetics, Kinetics, and Dynamics for Personalized Medicine / Burlington, Massachusetts: Jones & Bartlett Learning; 2014; pp. 3-37.
  27. Lown K., Bailey D., Fontana R. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression // J. Clin. Invest. - 1997; 99: 2545-53. [PubMed: 9153299]
  28. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. - 2013; 8 (Issue 12): e82562.
  29. Регистр больных муковисцидозом в Российской Федерации, 2013 год. Под ред. Н.Ю. Каширской / М.: МЕДПРАКТИКА-М, 2015, 64 с.
  30. Регистр больных муковисцидозом в Российской Федерации, 2014 год / М.: МЕДПРАКТИКА-М, 2015; 64 с.
  31. Recommendations for the classification of diseases as CFTR-related disorders // J. Cyst. Fibros. - 2011; 10 (Suppl. 2): 86-102.
  32. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. - 2013; 8 (Issue 12): e82562.
  33. Gaikovitch E., Cascorbi I., Mrozikiewicz P. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. - 2003; 59 (4): 303-12.
  34. Чурносов М.И., Полякова И.С., Пахомов С.П. и др. Молекулярные и генетические механизмы биотрансформации ксенобиотиков // Научные ведомости БелГУ. Серия: Медицина. Фармация. - 2011; 16 (111): 223-8.
  35. Plummer A., Wildman M., Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis // Cochrane Database Syst. Rev. - 2016; 9: CD006682. [Epub ahead of print] Review. PubMed PMID: 27582394.
  36. Westervelt P., Cho K., Bright D. et al. Drug-Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements // Pharmacy and Therapeutics. - 2014; 39 (9): 630-7.
  37. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. - 2013; 8 (Issue 12): e82562.
  38. Шабалова Л.И., Поликарпова С.В., Пивкина Н.В. и др. Опыт применения колистиметата натрия (колистина) при синегнойной инфекции у детей c муковисцидозом // Педиатрия. Журн. им. Г.Н. Сперанского. - 2016; 95 (6): 85-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Russkiy Vrach Publishing House